SAN DIEGO–(Small business WIRE)–ADARx Prescribed drugs, Inc., a biotechnology organization developing RNA-targeting therapeutics, now introduced the expansion of their management staff and development capabilities as a result of the appointment of Andrew Seacat, Ph.D., Government Director and Head of Toxicology.
“I am delighted to welcome Andrew to the ADARx team, as his wealth of experience in the biotech field will considerably improve our abilities,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “Andrew has deep knowledge throughout essential facets of progress from preclinical studies to NDA submission and his management provides fantastic benefit to the firm as we continue on to broaden our pipeline and advance programs to the clinic.”
Dr. Seacat has around 20 several years of experience in nonclinical drug growth, toxicology, and drug basic safety evaluation and, in his new part, will direct all GLP and non-GLP toxicology scientific studies for our RNA-focusing on therapeutics. Dr. Seacat was most a short while ago Senior Director, Pharmacology and Toxicology at Zogenix (a wholly owned subsidiary of UCB S.A.) exactly where he led authoring of all non-scientific sections of an NDA. Prior positions include things like Vice President, Preclinical Improvement at Latitude Prescription drugs and Senior Director, Preclinical Progress at La Jolla Pharmaceuticals. He also had rising roles of obligation in toxicology and drug safety at Allergan Pharmaceuticals, Amylin Pharmaceuticals, and 3M Healthcare Division. Dr. Seacat gained a Doctorate in Biochemical Molecular Toxicology and concluded a Postdoctoral Fellowship at Johns Hopkins College. Dr Seacat was also Diplomate of the American Board of Toxicology (DABT2001-2015).
ADARx Prescription drugs, Inc., situated in San Diego, is a biotechnology company committed to turning chopping-edge science into everyday living-saving therapeutics. ADARx is producing a proprietary RNA concentrating on system, like oligonucleotides for inhibition, degradation, and enhancing, with each other with novel oligonucleotide shipping and delivery systems. ADARx has a developing pipeline of RNA focusing on therapeutics for dealing with ailments throughout a array of therapeutic places which includes genetic, cardiometabolic, complement-mediated and central nervous procedure diseases. ADARx direct packages are at IND-enabling phase.